Holen Sie sich die Stockscreener-App
10.19
5.10%
0.48
Handel nachbörslich:
10.19
Schlusskurs vom Vortag:
$9.71
Offen:
$9.45
24-Stunden-Volumen:
2.50M
Relative Volume:
1.16
Marktkapitalisierung:
$1.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-35.14
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+6.86%
1M Leistung:
+23.70%
6M Leistung:
+71.51%
1J Leistung:
+220.91%
1-Tages-Spanne:
$9.28
$10.31
1-Wochen-Bereich:
$9.28
$10.31
52-Wochen-Spanne:
$2.36
$10.31
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.19 | 1.18B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics stock hits 52-week high at 10.16 USD - Investing.com India
Multi factor analysis applied to Trevi Therapeutics Inc.July 2025 Earnings & Verified Momentum Watchlists - newser.com
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap DownTime to Sell? - MarketBeat
Does Trevi Therapeutics Inc. show high probability of reboundPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com
Should I hold or sell Trevi Therapeutics Inc. stock in 2025July 2025 Volume & Community Consensus Picks - newser.com
How moving averages guide Trevi Therapeutics Inc. tradingJuly 2025 Pullbacks & Low Drawdown Investment Strategies - newser.com
Is Trevi Therapeutics Inc a good long term investmentMarket Timing Techniques & Insights From Wall Street Professionals - earlytimes.in
Is Trevi Therapeutics Inc. stock bottoming out2025 Volatility Report & Long-Term Growth Stock Strategies - newser.com
How to use Fibonacci retracement on Trevi Therapeutics Inc.2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Published on: 2025-10-10 03:52:14 - newser.com
What MACD and RSI say about Trevi Therapeutics Inc.Trade Entry Report & Long-Term Investment Growth Plans - newser.com
Trevi Therapeutics (NASDAQ:TRVI) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Candlestick signals on Trevi Therapeutics Inc. stock todayJuly 2025 Sentiment & Daily Volume Surge Trade Alerts - newser.com
Trevi Therapeutics announces oral presentation and abstracts at Chest 2025 Annual Meeting - MarketScreener
Trevi Therapeutics Announces Oral Presentation And Abstracts At Chest 2025 Annual Meeting - TradingView
Phase 2b CORAL results: Trevi Therapeutics to present nalbuphine ER Oct 21; RIVER 2a PROs poster - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $21.75 Consensus Target Price from Analysts - Defense World
Trevi Therapeutics, Inc. $TRVI Stock Position Boosted by Farther Finance Advisors LLC - Defense World
Trevi Therapeutics Inc. stock trend forecast2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
Analyzing net buyer seller activity in Trevi Therapeutics Inc.July 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighHere's What Happened - MarketBeat
Trevi Therapeutics stock hits 52-week high at 9.93 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week high at 9.93 USD - Investing.com
What analysts say about Trevi Therapeutics Inc stockBearish Engulfing Patterns & Tap Into the Fastest-Growing Companies - earlytimes.in
Will earnings trigger a reversal in Trevi Therapeutics Inc.Recession Risk & High Return Stock Watch Alerts - newser.com
Regression analysis insights on Trevi Therapeutics Inc. performancePortfolio Return Summary & Low Risk Growth Stock Ideas - newser.com
Rhumbline Advisers Buys 10,608 Shares of Trevi Therapeutics, Inc. $TRVI - Defense World
Analyzing recovery setups for Trevi Therapeutics Inc. investorsTrade Performance Summary & Precise Buy Zone Tips - newser.com
Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut - Yahoo Finance
Custom watchlist performance reports with Trevi Therapeutics Inc.Swing Trade & Reliable Trade Execution Plans - newser.com
Trading Recap: Will Trevi Therapeutics Inc. outperform tech stocksShort Setup & Smart Investment Allocation Tips - خودرو بانک
How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025 - Yahoo Finance
Is Trevi Therapeutics Inc. stock entering bullish territoryIPO Watch & Target Return Focused Picks - newser.com
Quarterly Risk: Will Trevi Therapeutics Inc. outperform its industry peersBull Run & AI Optimized Trade Strategies - خودرو بانک
Hedge Fund Moves: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Stock Summary & Fast Entry Momentum Alerts - خودرو بانک
Long term hold vs stop loss in Trevi Therapeutics Inc.Quarterly Market Review & Fast Gaining Stock Reports - newser.com
Market Recap: Can ProShares Trust ProShares UltraShort Russell2000 grow without dilution2025 Technical Patterns & Safe Capital Growth Stock Tips - khodrobank.com
Market Catalysts: Is Trevi Therapeutics Inc forming a breakout patternPortfolio Gains Report & Fast Moving Stock Trade Plans - khodrobank.com
Combining machine learning predictions for Trevi Therapeutics Inc.Weekly Trade Recap & Low Risk Profit Maximizing Plans - newser.com
Trevi Therapeutics to present two phase 2a River trial posters at ERS Congress 2025 - MarketScreener
Trevi Therapeutics To Present Two Phase 2a River Trial Posters At ERS Congress 2025 - TradingView
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 - PR Newswire
Will Trevi Therapeutics Inc outperform its industry peers2025 Trading Recap & Long-Term Capital Growth Strategies - khodrobank.com
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4.6%Here's What Happened - MarketBeat
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):